Early effect of bivalent human papillomavirus vaccination on cytology outcomes in cervical samples among young women in the Netherlands
Cancer Medicine · 2023
DOI: 10.1002/cam4.5842 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Tessa M Schurink-van 't Klooster und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department National Immunisation Programme, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthove…. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Uterine Cervical Dysplasia, Papillomavirus Infections, Papillomavirus Vaccines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The first HPV‐vaccine eligible cohorts in the Netherlands will enter the cervical screening program in 2023. However, a substantial number of young women already have had a cervical sample taken before entry into the regular screening program. This study was initiated to explore early effects of HPV vaccination on detection of cytological abnormalities in cervical samples of women younger than the screening age.
Methods
Results of cervical samples were obtained from the Dutch National Pathology Databank (PALGA) and were linked to the women's HPV vaccination status from the national vaccination registry (Praeventis) ( N = 42,171). Occurrence of low‐grade and high‐grade squamous intraepithelial lesions or worse (LSIL and HSIL+) and high‐risk HPV positive tests (hrHPV) in the first cervical sample were compared between vaccinated and unvaccinated women by multivariable logistic regression analysis, corrected for age at cervical sampling and age of vaccination (12/13 years, ≥ = 14 years).
Results
For fully vaccinated women (three‐ or two‐dose schedule), statistically significant reductions were seen for all outcomes compared to unvaccinated women (hrHPV: adjusted OR, 0.70, 95% CI, 0.63–0.79; LSIL: 0.70, 0.61–0.80; HSIL+: 0.39, 0.30–0.51).
Conclusions
By linking nation‐wide registries on pathology and vaccination, we show significant beneficial early effects of HPV‐vaccination on LSIL, HSIL+, CIN3/AIS/carcinoma and hrHPV detection in young women upto 24 years of age who have a cervical sample taken before entry into the cervical cancer screening program.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department National Immunisation Programme, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
- PALGA, Houten, The Netherlands.
- Department of Pathology, Erasmus Medical Centre, Rotterdam, The Netherlands.
- Department of Epidemiology and Data Science, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
ORCID-Profile: Tessa M Schurink-van 't Klooster
Zitieren
APA
Schurink-van 't Klooster, T. M., Siebers, A. G., Hoes, J., van Kemenade, F. J., Berkhof, J., Bogaards, J. A., & de Melker, H. E. (2023). Early effect of bivalent human papillomavirus vaccination on cytology outcomes in cervical samples among young women in the Netherlands. Cancer Medicine. https://doi.org/10.1002/cam4.5842
Vancouver
Schurink-van 't Klooster TM, Siebers AG, Hoes J, van Kemenade FJ, Berkhof J, Bogaards JA, et al. Early effect of bivalent human papillomavirus vaccination on cytology outcomes in cervical samples among young women in the Netherlands. Cancer Medicine. 2023. doi:10.1002/cam4.5842
BibTeX
@article{SchurinkvantKlooster2023,
author = {Schurink-van 't Klooster, Tessa M and Siebers, Albert G and Hoes, Joske and van Kemenade, Folkert J and Berkhof, Johannes and Bogaards, Johannes A and de Melker, Hester E},
title = {Early effect of bivalent human papillomavirus vaccination on cytology outcomes in cervical samples among young women in the Netherlands},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.5842}
}
EUVIMED